Sander P, Stücker M, Hermes N, Hoffmann K, Altmeyer P
Dermatologische Klinik, Ruhr-Universität, Bochum.
Hautarzt. 1998 Apr;49(4):291-4. doi: 10.1007/s001050050743.
In a randomized study 30 patients with chronic stationary psoriasis were treated with 3 different topical schemes. Group 1 (n = 10) received monotherapy (dithranol (D) twice a day, D/D), group 2 (n = 10) calcipotriol mornings/dithranol evenings (calcipotriol (C)/dithranol (D) C/D) and 3 (mometasone (M) mornings/dithranol (D) evenings, M/D). During the therapy period of 4 weeks we documented the PASI-Score as well as infiltration, erythema and desquamation weekly. The M/D group revealed in the first week a significantly faster reduction of the PASI-score (5.3) than in the D/D group (PASI 13.22). The C/D group (PASI 10.5) show a not significantly faster reduction. After 4 weeks of treatment and after a follow period of 6 weeks there were similar PASI-Scores in all groups. There were less side-effects in the M/D group than in the others. The beginning, more anti-psoriatic effectiveness was achieved by the mometasone/dithranol combination than the other schemes. In the long term, the effects were similar.
在一项随机研究中，30例慢性静止期银屑病患者接受了3种不同的局部治疗方案。第1组（n = 10）接受单一疗法（地蒽酚（D）每日两次，D/D），第2组（n = 10）早上使用卡泊三醇/晚上使用地蒽酚（卡泊三醇（C）/地蒽酚（D），C/D），第3组（早上使用莫米松（M）/晚上使用地蒽酚（D），M/D）。在4周的治疗期内，我们每周记录银屑病面积和严重程度指数（PASI）评分以及浸润、红斑和脱屑情况。M/D组在第一周显示PASI评分的降低（5.3）明显快于D/D组（PASI 13.22）。C/D组（PASI 10.5）显示降低速度没有明显更快。治疗4周后及6周的随访期后，所有组的PASI评分相似。M/D组的副作用比其他组少。开始时，莫米松/地蒽酚联合用药比其他方案更能达到抗银屑病效果。从长期来看，效果相似。
